Analysis of the effect of mouthwash prepared with mannitol on tyrosine kinase receptor inhibitor oral mucosal adverse reactions in patients with liver cancer

Electronic Journal of Liver Tumor ›› 2023, Vol. 10 ›› Issue (2): 51-54.

• Nursing field • Previous Articles Next Articles

Analysis of the effect of mouthwash prepared with mannitol on tyrosine kinase receptor inhibitor oral mucosal adverse reactions in patients with liver cancer

Wu Shu¹, Liu Yan¹, Zhan Zhengyin¹, Li Xiaoqing¹, Liu Zirong¹, Huang Lihui², Li Caiyun³, Wang Jingya³, Lu Hong^4,*

1. Department of Hepatobiliary Surgery, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, Guangdong, China;
2. Intensive Care Unit, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, Guangdong, China;
3. Department of Hepatobiliary Surgery, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;
4. Department of Nursing, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, Guangdong, China

Received:2022-10-08 Online:2023-06-30 Published:2023-08-14

Abstract

Abstract: Objective: Tyrosine kinase transmembrane receptor inhibitors are widely used in the clinical treatment of liver cancer, and oral mucosal adverse reactions may occur. This study is to explore the effect of mannitol, lidocaine, dexamethasone and mouthwash in such patients.
Method: In this paper, 46 patients with liver cancer who were treated with sorafenib, lenvatinib, regorafenib or cetuximab were selected as the research objects (all oral mask reactions were grade 2-3). They were randomly divided into 23 cases in the observation group and 23 cases in the control group. The control group used mannitol, lidocaine and dexamethasone to rinse the mouth when adverse reactions to the oral mask occurred, and the observation group was.
Result: The effect of oral mucosal adverse reactions in the observation group was later than that in the control group and the symptoms were milder. The difference between the two groups was significant (P<0.05).
Conclusion: The mannitol, lidocaine and dexamethasone preparation has a good effect on the oral mucosal side effects of the tyrosine kinase transmembrane receptor inhibitor, and it is worthy of clinical application. This article provides references for oncology nursing workers to deal with related adverse reactions.

Key words: Liver cancer, Oral mucositis, Targeted therapy, Mouthwash

Wu Shu, Liu Yan, Zhan Zhengyin, Li Xiaoqing, Liu Zirong, Huang Lihui, Li Caiyun, Wang Jingya, Lu Hong. Analysis of the effect of mouthwash prepared with mannitol on tyrosine kinase receptor inhibitor oral mucosal adverse reactions in patients with liver cancer[J]. Electronic Journal of Liver Tumor, 2023, 10(2): 51-54.

References

[1] MOEINI A, SIA D, ZHANG Z, et al.Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity[J]. J Hepatol, 2017, 66(5): 952-961.
[2] 赵宏, 蔡建强. 原发性肝癌非手术治疗的现状与展望[J]. 中华肝胆外科杂志, 2011, 17(7): 527-530.
[3] LANG D S.Interventions for preventing oral mucositis for patients with cancer receiving treatment[J]. Clin J Oncol Nurs, 2013, 17(3): 340.
[4] EILERS J, MILLION R.Prevention and management of oral mucositis in patients with cancer[J]. Semin Oncol Nurs, 2007, 23(3): 201-212.
[5] BRUIX J, QIN S, MERLE P, et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064): 56-66.
[6] FREITES-MARTINEZ A, SANTANA N, ARIAS-SANTIAGO S, et al.Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed), 2021, 112(1): 90-92.
[7] 中国抗癌协会肿瘤护理专业委员会. 中国癌症症状管理实践指南——口腔黏膜炎[J]. 护士进修杂志, 2020, 35(20): 1871-1878.
[8] WANG Y, HE F, ZHANG H, et al.Preparation and identification of an anti-idiotypic antibody antagonist (FG8) for EGFR that shows potential activity against liver cancer cells[J]. Biotechnol Letters, 2021, 43(2): 369-382.
[9] KANAGALINGAM J, WAHID M I A, LIN J C, et al. Patient and oncologist perceptions regarding symptoms and impact on quality-of-life of oral mucositis in cancer treatment: results from the Awareness Drives Oral Mucositis PercepTion (ADOPT) study[J]. Support Care Cancer, 2018, 26(7): 2191-2200.
[10] LALLA R V, BOWEN J, BARASCH A, et al.Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy[J]. Cancer, 2014, 120(10): 1453-1461.
[11] ROTHSCHILD S I, BETTICHER D, ZENHÄUSERN R, et al. Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study[J]. Cancer Chemother Pharmacol, 2019, 84(4): 881-889.
[12] 程红霞, 罗彦, 程红玉. 口腔冷疗法预防放疗联合化疗移植预处理患者口腔黏膜炎11例疗效观察[J].临床医药实践, 2017, 26(8): 613-616.
[13] 邱志锋, 吴苗, 邱爱钗. 蜂胶防治乳腺癌化疗致口腔黏膜炎的疗效评价[J]. 循证护理, 2021, 7(13): 1825-1828.
[14] HILL A, KISS N, HODGSON B, et al.Associations between nutritional status,weight loss,radiotherapy treatment toxicity and treatment outcomes in gastrointestinal cancer patients[J]. Clin Nutr, 2011, 30(1): 92-98.
[15] PHIPPEN N T, LOWERY W J, BARNETT J C, et al.Evaluation of the Patient Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: a pilot study[J]. Gynecol Oncol, 2011, 123(2): 360-364.

Analysis of the effect of mouthwash prepared with mannitol on tyrosine kinase receptor inhibitor oral mucosal adverse reactions in patients with liver cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Guo Xuerong, Cao Ling, Zhang Ruifeng, Wang Xinchen, Qiao Nan, Zhang Yongzhen. Analysis of incidence and mortality of liver cancer in Shanxi cancer registries, 2019 [J]. Electronic Journal of Liver Tumor, 2023, 10(2): 27-32.
[2]	Sun Dibo, Ma Haiyan, Guo Fei, Wu Xueliang. Relationship between nutritional status and sarcopenia incidence in patients with primary liver cancer [J]. Electronic Journal of Liver Tumor, 2023, 10(1): 25-30.
[3]	Zeng Zhaochong^*. Progresses for stereotactic radiotherapy in primary liver cancer [J]. Electronic Journal of Liver Tumor, 2022, 9(4): 12-14.
[4]	Shan Tianhao¹, An Lan¹, Xu Mengyuan¹, Zeng Hongmei^1,, Cai Jianqiang^2,. Global liver cancer and gallbladder cancer incidence and mortality in 2020 [J]. Electronic Journal of Liver Tumor, 2022, 9(4): 46-51.
[5]	Zhou Tengchao^*, Tian Zhuangbo, Long Lin. Efficacy and safety of sequential transcatheter arterial chemoembolization with ¹²⁵I seed strip combined with portal vein stent implantation guided by double guidance technology in the treatment of primary hepatocellular carcinoma complicated with portal vein tumor thrombus [J]. Electronic Journal of Liver Tumor, 2022, 9(4): 52-58.
[6]	Cheng Yangyang, Li Huichao, Liu Shuo, Yang Lei, Zhang Xi, Li Qingyu, Li Haoxin, Wang Ning. Incidence and mortality of liver cancer in Beijing, 2003—2017 [J]. Electronic Journal of Liver Tumor, 2022, 9(3): 12-16.
[7]	Huang Yongchu, Cai Ruiqiang, Liu Nian, Zhou Fengsheng, Mao Xianshuang. Analysis of postoperative pain score and risk of lung infection after liver resection based on propensity score matching [J]. Electronic Journal of Liver Tumor, 2022, 9(3): 17-21.
[8]	Chen Qiong, Liu Yin, Liu Shuzheng, Guo Lanwei, Zheng Liyang, Xu Huifang, Wang Xiaoyang, Wang Hong, Sun Xibin, Zhang Shaokai. Report of liver cancer incidence and mortality in 2016 and the time trends during 2010―2016 in Henan Province, China [J]. Electronic Journal of Liver Tumor, 2022, 9(2): 7-12.
[9]	Zhang Jiaoyan, Zhao Liang, Wei Wei, Ren Xuejun, Wang Chao, Sun Rui, Yu Lei, Yang Min. Bibliometrics and visual analysis of psychological intervention for primary liver cancer patients [J]. Electronic Journal of Liver Tumor, 2022, 9(2): 41-48.
[10]	Zhu Ying, Gu Xinglu, Zhao Xiaohang, Sun Yulin. Clinical significance and functional analysis of NADH: ubiquinone oxidoreductase complex assembly factor 2 in liver cancer [J]. Electronic Journal of Liver Tumor, 2022, 9(1): 29-35.
[11]	Du Honglei, Zhang Feng, Zhang Yonghua, Ban Zhichao, Wang Xu. Study on the mechanism of total glycosides of ranunculus japonicus inhibiting the proliferation, migration and invasion of liver cancer cells through the circ_0079593/miR-324-5p pathway [J]. Electronic Journal of Liver Tumor, 2022, 9(1): 48-54.
[12]	Li Cunya, Fu Shujuan, Li Yun, Zhong Zhixian, Wang Zhiying, Zhong Yi. Progress on immune mechanism of traditional Chinese medicine regulating gut microbiota and its metabolites in the occurrence and development of liver cancer [J]. Electronic Journal of Liver Tumor, 2022, 9(1): 61-64.
[13]	Niu Huimin, Wang Zhiheng, Gao Shixin, Zeng Qian, Li Yinghui, Han Yue. Application and progress of Yttrium-90 therapy in liver malignant tumors [J]. Electronic Journal of Liver Tumor, 2021, 8(4): 36-40.
[14]	He Qiang, Zhou Lin. To establish a comprehensive prevention and treatment system based on rapamycin for cancer recurrence after liver transplantation [J]. Electronic Journal of Liver Tumor, 2021, 8(3): 1-7.
[15]	Xie Yan, Zhang Weiqi, Sun Jisan, Jiang Wentao. Comparison of comprehensive therapy and local therapy of recurrence after liver transplantation in patients with hepatocellular carcinoma beyond Milan criteria [J]. Electronic Journal of Liver Tumor, 2021, 8(3): 12-16.